Mitsubishi UFJ Asset Management Co., Ltd. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
Mitsubishi UFJ Asset Management Co., Ltd. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$203,529
-17.8%
4,484
+1.7%
0.00%
-100.0%
Q2 2023$247,465
+16.9%
4,408
-5.8%
0.00%0.0%
Q1 2023$211,676
+18.6%
4,680
+7.5%
0.00%
Q4 2022$178,473
-38.9%
4,353
-2.5%
0.00%
-100.0%
Q3 2022$292,000
+9.8%
4,464
+2.0%
0.00%0.0%
Q2 2022$266,000
+12.7%
4,376
+16.2%
0.00%0.0%
Q1 2022$236,000
-14.2%
3,767
+8.7%
0.00%0.0%
Q4 2021$275,000
-12.1%
3,467
+23.9%
0.00%
-50.0%
Q3 2021$313,000
-30.9%
2,7990.0%0.00%0.0%
Q2 2021$453,000
+13.0%
2,799
-15.0%
0.00%
-33.3%
Q1 2021$401,000
+16.2%
3,294
+46.0%
0.00%0.0%
Q4 2020$345,000
+38.0%
2,256
-24.4%
0.00%
+50.0%
Q3 2020$250,000
+13.6%
2,985
-0.5%
0.00%
-33.3%
Q2 2020$220,000
+98.2%
2,999
+14.9%
0.00%
+50.0%
Q1 2020$111,000
-7.5%
2,610
+29.7%
0.00%0.0%
Q4 2019$120,000
-20.0%
2,013
-44.9%
0.00%0.0%
Q3 2019$150,000
+4.2%
3,655
+19.4%
0.00%0.0%
Q2 2019$144,000
-4.6%
3,060
-27.5%
0.00%
-33.3%
Q1 2019$151,000
+34.8%
4,220
+5.8%
0.00%0.0%
Q4 2018$112,000
+13.1%
3,987
+79.4%
0.00%
+50.0%
Q3 2018$99,0002,2220.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders